Iopanoic acid
Based on 3 publication(s) in Google Scholar
Iopanoic acid is an inhibitor of 5'-Deiodinase and also an iodinated contrast medium.
For research use only. We do not sell to patients.
- Purity: 98.58%
- CAS No.: 96-83-3
- Formula: C11H12I3NO2
- Molecular Weight:570.93
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Iopanoic acid
More
Biological Activity
5'-Deiodinase[1]
The thyrotropin-releasing-hormone (TRH)-induced thyrotropin (TSH) release from the pituitary fragments is inhibited by 3,5,3'-triiodothyronin (T3) (10-7 M), by triiodothyroacetic acid (10-7 to 10-7 M), and by high concentrations of iodide (10-4 or 10-5 M). Iopanoic acid has no significant effect at the concentrations tested[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 96-83-3
-
Appearance Solid
-
Molecular Weight 570.93
-
Formula C11H12I3NO2
-
Color White to off-white
-
SMILES
O=C(O)C(CC)CC1=C(I)C=C(I)C(N)=C1I
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Environ Sci Technol
IodoFinder: Machine Learning-Guided Recognition of Iodinated Chemicals in Nontargeted LC-MS/MS Analysis. [Abstract]2025 Mar 11;59(9):4530-4539. PMID: 40015982 -
Ecotoxicol Environ Saf
Cadmium exposure activates mitophagy through downregulating thyroid hormone receptor/PGC1α signal in preeclampsia. [Abstract]2024 May:276:116259. PMID: 38581905 -
Endocrinology
T3-THR Signaling Governed by DIO2 Contributes to Endometrial Receptivity by Regulating Epithelial Cell Membrane Fluidity. [Abstract]2025 Apr 18:bqaf070. PMID: 40250967
Solvent & Solubility
DMSO : 250 mg/mL (437.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Rat pituitary fragments are superfused by Medium-199. After a 90 min equilibration period, the superfusion is continued for 135 min with or without inclusion into the superfusion medium of 3,5,3'-triiodothyronin (T3) 10-7 M, triiodothyroacetic acid (TRIAC) (stock solution 10-4 M in 20% methanol, final concentrations 10-8 to 10-6 M), Iopanoic acid (stock solution 10-3 M in 0.2 M NaOH, final concentrations 10-7 to 10-5 M), or potassium iodide 10-7 to 10-4 M. The superfusion is followed by a 6-min pulse of thyrotropin-releasing-hormone (TRH)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Wistar rats initially weighing 180 to 200 g are used. The administration of Iopanoic acid (IOP) is started at day 18 of gestation. Pregnant rats are injected subcutaneously with 10 mg of Iopanoic acid every 12 h, from day 18 of gestation to 12 h before they are killed on the morning of day 20 or 22 of gestation. Control animals receive the vehicle solution with identical timing. Iopanoic acid effectiveness in decreasing interscapular brown adipose tissue (IBAT) nuclear 3,5,3'-triiodothyronin (T3) is assessed by Iopanoic acid (IOP) administration to adult male rats (220 to 250 g body weight) following the same dose and time schedule as in pregnant dams during two days. Caesarean sections are performed at 18 (only untreated animals), 20 and 22 days of gestation. Fetuses are killed by decapitation, and IBAT, brain, and liver are removed. Tissue samples are immediately frozen in liquid nitrogen with the exception of brown fat from several 22 day-old fetuses, which is directly homogenized in 0.25 M sucrose for mitochondria isolation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tuca A, et al. Inhibition of iodothyronine 5'-deiodinase by iopanoic acid does not block nuclear T3 accumulation during rat fetal development. Pediatr Res. 1994 Jan;35(1):91-5. [Content Brief]
[2]. Szabolcs I, et al. Effects of triiodothyronine, triiodothyroacetic acid, iopanoic acid and iodide on the thyrotropin-releasing hormone-induced thyrotropin release from superfused rat pituitary fragments. Acta Endocrinol (Copenh). 1991 Oct;125(4):427-34. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7515 mL | 8.7576 mL | 17.5153 mL | 43.7882 mL |
| 5 mM | 0.3503 mL | 1.7515 mL | 3.5031 mL | 8.7576 mL | |
| 10 mM | 0.1752 mL | 0.8758 mL | 1.7515 mL | 4.3788 mL | |
| 15 mM | 0.1168 mL | 0.5838 mL | 1.1677 mL | 2.9192 mL | |
| 20 mM | 0.0876 mL | 0.4379 mL | 0.8758 mL | 2.1894 mL | |
| 25 mM | 0.0701 mL | 0.3503 mL | 0.7006 mL | 1.7515 mL | |
| 30 mM | 0.0584 mL | 0.2919 mL | 0.5838 mL | 1.4596 mL | |
| 40 mM | 0.0438 mL | 0.2189 mL | 0.4379 mL | 1.0947 mL | |
| 50 mM | 0.0350 mL | 0.1752 mL | 0.3503 mL | 0.8758 mL | |
| 60 mM | 0.0292 mL | 0.1460 mL | 0.2919 mL | 0.7298 mL | |
| 80 mM | 0.0219 mL | 0.1095 mL | 0.2189 mL | 0.5474 mL | |
| 100 mM | 0.0175 mL | 0.0876 mL | 0.1752 mL | 0.4379 mL |